2021
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients
Sivakumar A, Madden L, DiDomizio E, Eller A, Villanueva M, Altice FL. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients. International Journal Of Drug Policy 2021, 101: 103570. PMID: 34954493, PMCID: PMC8685180, DOI: 10.1016/j.drugpo.2021.103570.Peer-Reviewed Original ResearchConceptsOpioid use disorderHepatitis C virusSyringe services programDifferentiated care modelPerson visitsC virusCare modelUse disordersInitiation of DAAChronic HCV infectionEvidence-based treatmentsCOVID-19Initial phlebotomyVirological responseHCV infectionHCV treatmentAdditional patientsElevated riskPatientsClient-centred approachPWIDHIVPerson contactTreatment demandLaboratory screeningAcceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study
Shelby T, Zhou X, Barber D, Altice F. Acceptability of an mHealth App That Provides Harm Reduction Services Among People Who Inject Drugs: Survey Study. Journal Of Medical Internet Research 2021, 23: e25428. PMID: 34259640, PMCID: PMC8319773, DOI: 10.2196/25428.Peer-Reviewed Original ResearchMeSH KeywordsHarm ReductionHIV InfectionsHumansMaleMiddle AgedMobile ApplicationsPharmaceutical PreparationsSubstance Abuse, IntravenousSurveys and QuestionnairesTelemedicineConceptsSyringe services programHarm reduction servicesReduction servicesSecondary outcomesMHealth appsParticipant characteristicsHarm reduction needsHome deliveryMost participantsRespondent-driven samplingPrimary outcomeSuboptimal accessIndependent correlatesMedical recordsDrug injectionMobile health appsPWIDSummary scoresMedication remindersSSP usePoisson regressionUnstable housingVulnerable populationsSyringe deliveryHealth appsPurposeful Fentanyl Use and Associated Factors among Opioid-Dependent People Who Inject Drugs
Chandra DK, Altice FL, Copenhaver MM, Zhou X, Didomizio E, Shrestha R. Purposeful Fentanyl Use and Associated Factors among Opioid-Dependent People Who Inject Drugs. Substance Use & Misuse 2021, 56: 979-987. PMID: 33769199, DOI: 10.1080/10826084.2021.1901931.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidConnecticutCross-Sectional StudiesFentanylHumansOpioid-Related DisordersPharmaceutical PreparationsSubstance Abuse, IntravenousConceptsOpioid-dependent PWIDFentanyl useOpioid-dependent peopleIndependent correlatesSevere depressionSex-related risk behaviorsMethadone-maintained patientsMultivariable logistic regressionOpioid-related mortalityRecent cocaine useCross-sectional surveySelf-reported drugMethadone dosageYoung PWIDDaily injectionsMethadone clinicsAssociated FactorsFentanyl exposureHigh prevalencePWIDSynthetic opioidsCocaine useYounger ageRisk behaviorsLogistic regressionUse of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust
Zhou X, Altice FL, Chandra D, Didomizio E, Copenhaver MM, Shrestha R. Use of Pre-exposure Prophylaxis Among People Who Inject Drugs: Exploratory Findings of the Interaction Between Race, Homelessness, and Trust. AIDS And Behavior 2021, 25: 3743-3753. PMID: 33751313, DOI: 10.1007/s10461-021-03227-7.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsCross-Sectional StudiesHIV InfectionsHumansIll-Housed PersonsPharmaceutical PreparationsPre-Exposure ProphylaxisSubstance Abuse, IntravenousTrustConceptsPre-exposure prophylaxisPrEP useProvider trustPatient-level factorsOpioid-dependent patientsLogistic regression analysisNon-homeless participantsHomeless participantsRace/ethnicityEligibility criteriaCross-sectional dataPrEPProphylaxisMethadoneRegression analysisDrugsExploratory findingsParticipantsPotential moderatorsPWIDPatientsSignificant moderatorWillingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment
Ni Z, Altice FL, Wickersham JA, Copenhaver MM, DiDomizio EE, Nelson LE, Shrestha R. Willingness to initiate pre-exposure prophylaxis (PrEP) and its use among opioid-dependent individuals in drug treatment. Drug And Alcohol Dependence 2021, 219: 108477. PMID: 33422864, PMCID: PMC7946167, DOI: 10.1016/j.drugalcdep.2020.108477.Peer-Reviewed Original ResearchConceptsOpioid-dependent individualsPre-exposure prophylaxisPrEP useHIV riskHealthcare providersSex-related risk behaviorsMultivariable logistic regression analysisAwareness of PrEPUrban methadone clinicMultiple logistic regressionDisproportionate HIV burdenLogistic regression analysisCross-sectional surveyHIV burdenHIV infectionHIV testingIndependent correlatesMethadone clinicsDrug treatmentRisk behaviorsLogistic regressionPrEPPrevious useHigher likelihoodProphylaxis
2020
Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs
Shrestha R, DiDomizio EE, Kim RS, Altice FL, Wickersham JA, Copenhaver MM. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs. Journal Of Substance Use And Addiction Treatment 2020, 117: 108058. PMID: 32811633, PMCID: PMC7438607, DOI: 10.1016/j.jsat.2020.108058.Peer-Reviewed Original ResearchMeSH KeywordsAnti-HIV AgentsFemaleHIV InfectionsHomosexuality, MaleHumansMalePatient Acceptance of Health CarePharmaceutical PreparationsPre-Exposure ProphylaxisThailandConceptsPre-exposure prophylaxisInjectable pre-exposure prophylaxisLAI-PrEPOral pre-exposure prophylaxisLong-term side effectsSelf-reported HIV risk behaviorsBangkok Tenofovir StudyEvidence-based HIVHigh-risk PWUDImportant key populationHIV-negative peopleOpioid use disorderHIV risk behaviorsHIV prevention effortsAddiction treatment programsDaily PrEPOral PrEPAdherence challengesIndependent correlatesFemale sexClinical trialsHIV preventionIndependent factorsSide effectsUse disordersModeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States
Zelenev A, Li J, Shea P, Hecht R, Altice FL. Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States. Clinical Infectious Diseases 2020, 72: 755-763. PMID: 32060534, PMCID: PMC7935393, DOI: 10.1093/cid/ciaa142.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsConnecticutHepacivirusHepatitis CHumansPharmaceutical PreparationsSubstance Abuse, IntravenousUnited StatesConceptsOpioid agonist therapySyringe services programHepatitis C virus (HCV) treatmentC virus treatmentHCV prevalenceHCV microeliminationHCV TasPHCV treatmentPrevention strategiesVirus treatmentTasP strategyHigh HCV prevalenceMicroelimination of HCVHuman immunodeficiency virusHCV treatment coverageOAT coverageAgonist therapyImmunodeficiency virusTreatment coverageMicroeliminationPrevention impactPrevalenceComplimentary interventionsHCVPWID
2019
Online HIV information seeking and pre-exposure prophylaxis awareness among people who use drugs
Ranjit YS, Shrestha R, Copenhaver M, Altice FL. Online HIV information seeking and pre-exposure prophylaxis awareness among people who use drugs. Journal Of Substance Use And Addiction Treatment 2019, 111: 16-22. PMID: 32087834, PMCID: PMC7039922, DOI: 10.1016/j.jsat.2019.12.010.Peer-Reviewed Original ResearchMeSH KeywordsCross-Sectional StudiesHIV InfectionsHumansInformation Seeking BehaviorPharmaceutical PreparationsPre-Exposure ProphylaxisSubstance Abuse, IntravenousConceptsHuman immunodeficiency virusHIV informationMethadone treatmentPre-exposure prophylaxis (PrEP) awarenessPre-exposure prophylaxisNew HIV diagnosesHIV-negative PWUDBehavior change continuumCross-sectional surveyMethods of preventionAddiction treatment programsHIV diagnosisImmunodeficiency virusInjection drugsHIV preventionHigh riskGeneral populationSex partnersOverall healthTreatment programPrEPDrugsPWUDChange continuumRisk